Search

Figure S2A

Tables S1, S2, S3, S4, S5

Studies based on deep ocean drilling cores points to North-East Greenland as a focal point for ice sheet accumulation incurring much earlier than the Pleistocene Northern Hemisphere glaciation. The build-up of marine-based ice sheets in these parts is critical to the cooling of the Nordic Seas and the Arctic Ocean, considered as a pre-condition for the modern ocean “conveyor belt” circulation. However, proximal sedimentary records that can shed light on the timing and climate background of early Greenland Ice Sheet evolution are lacking. In 2008 a series of shallow cores were drilled by the Kanumas consortium on the NorthEast Greenland shelf and Cenozoic sediments were recovered at several sites. Here we present litho- and palynostratigraphic information, along with new cosmogenic isotope results, of a 110 m long sediment core (Kanumas 13). The core study, supported by regional seismic data, suggests that ice streams may have been active on the North-East Greenland margin since middle-late Miocene. Geochemistry and magnetic susceptibility data indicate that an abrupt change in sediment source occurred at 50.8 m. The shift in provenance is accompanied by a transition to more open marine conditions. The implications for the Greenland Ice Sheet and Artic climate development will be addressed in the presentation.

Petermann Fjord is a deep (> 1000 m) fjord that incises the coastline of northwest Greenland and was carved by an expanded Petermann Glacier, one of the six largest outlet glaciers draining the modern Greenland Ice Sheet (GrIS). Between 5–70 m of unconsolidated glacigenic material infills in the fjord and adjacent Nares Strait, deposited as the Petermann and Nares Strait ice streams retreated through the area after the Last Glacial Maximum. We have investigated the deglacial deposits using seismic stratigraphic techniques and have correlated our results with high-resolution bathymetric data and core lithofacies. We identify six seismo-acoustic facies in more than 3500 line-km of sub-bottom and seismic-reflection profiles throughout the fjord, Hall Basin and Kennedy Channel. Seismo-acoustic facies relate to: bedrock or till surfaces (Facies I); subglacial deposition (Facies II); deposition from meltwater plumes and icebergs in quiescent glaciomarine conditions (Facies III, IV); deposition at grounded ice margins during stillstands in retreat (grounding-zone wedges; Facies V); and the redeposition of material down slopes (Facies IV). These sediment units represent the total volume of glacial sediment delivered to the mapped marine environment during retreat. We calculate a glacial sediment flux for the former Petermann Ice Stream as 1080–1420 m3 a−1 per meter of ice stream width and an average deglacial erosion rate for the basin of 0.29–0.34 mm a−1. Our deglacial erosion rates are consistent with results from Antarctic Peninsula fjord systems but are several times lower than values for other modern GrIS catchments. This difference is attributed to fact that large volumes of surface water do not access the bed in the Petermann system and we conclude that glacial erosion is limited to areas overridden by streaming ice in this large outlet glacier setting. Erosion rates are also presented for two phases of ice retreat and confirm that there is significant variation in these rates over a glacial-deglacial transition. Our new fluxes and erosion rates show that the Petermann Ice Stream was approximately as efficient as the palaeo-Jakobshavn Isbrae at eroding, transporting and delivering sediment to its margin during early deglaciation.

Purpose: Patritumab plus cetuximab with platinum as first-line therapy for patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) was evaluated for safety and to determine the recommended phase II combination dose. Patients and Methods: Patients aged ≥18 years with confirmed R/M SCCHN received intravenous patritumab (18 mg/kg loading dose; 9 mg/kg maintenance dose every 3 weeks) + cetuximab (400 mg/m2 loading dose; 250 mg/m2 maintenance dose weekly) + cisplatin (100 mg/m2 every 3 weeks) or carboplatin (AUC of 5) for six cycles or until toxicity, disease progression, or withdrawal. Primary endpoints were dose-limiting toxicities [DLT; grade ≥3 (21-day observation period)] and treatment-emergent adverse events (TEAE). Pharmacokinetics, human antihuman antibodies (HAHA), tumor response, progression-free survival (PFS), and overall survival (OS) were assessed. Results: Fifteen patients completed a median (range) of 8.7 (2.0–20.7) patritumab cycles. No DLTs were reported. Serious adverse events were reported in 9 patients (patritumab-related n = 4). TEAEs (N = 15 patients) led to patritumab interruption in 7 patients. Patritumab-related dose reductions were reported in 1 patient. Patritumab (18 mg/kg) pharmacokinetics (N = 15) showed mean (SD) AUC0–21d of 2,619 (560) μg/day/mL and maximum concentration of 499.9 (90.4) μg/mL. All patients were HAHA-negative at study end (single, transient low titer in 1 patient). Tumor response rate (complete plus partial response; N = 15) was 47%. Median (95% confidence interval) PFS and OS (N = 15) were 7.9 (3.7–9.7) and 13.5 (6.6–17.5) months, respectively. Conclusions: Patritumab (18 mg/kg loading dose, 9 mg/kg maintenance dose) plus cetuximab/platinum was tolerable, active in SCCHN, and selected as the phase II dose regimen.